Diagnostics serve to determine whether a specified disease or disease process is present in a living organism and anticipate disease earlier and better. The quality of research and development in the BioAlps cluster encourages innovative start-ups and multinationals alike to work on diagnostics for conditions ranging from celiac disease to HIV/AIDS. Diagnostics is a high growth market, with the global IVD market predicted to grow to US$ 84 billion by 2023. In Switzerland, 8% of medtech manufacturers produce in vitro diagnostics, which represented some US$365 million in 20151. There is rapid growth in new segments including molecular diagnostics, point of care and companion diagnostics2.
“THE GLOBAL IVD MARKET IS PREDICTED TO GROW TO US$ 84 BILLION BY 2023.”
The BioAlps cluster gathers together the com petences and knowhow of many innovative companies which are developing diagnosticsfor earlier detection of HIV, different cancers, infectious diseases and other conditions. The region is an outstanding place to develop a broad scope of diagnostics ranging from in vitro diagnostics (IVDs), sophisticated tech nologies performed in clinical laboratories, to simple self-tests, such as for pregnancy. This is why Aimago and Abionic, two start-up/spinoffs of the Swiss Federal Institute of Technol ogy Lausanne (EPFL) and mid-cap companies like Bracco Imaging have set up in the region.
The fast growth rate of diagnostic imaging has led Roche to select Geneva University (UNIGE) as a Centre of Excellence for diag nostic research, aimed at personalized medical diagnosis and treatment, using a translational approach in a strategic partnership including the University Hospitals of Geneva (HUG) and the Swiss Institute of Bioinformatics (SIB).
Using all the resources of Western Switzerland, companies are successfully accessing research, technology transfer, funding, technological knowhow and much more besides. For exam ple, companies and research institutions in the cluster are working on systems that can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sam ple types; biomarkers for hormone depend ent cancers; determining unique biomarkers patients’ tumors and correlating biomarkers to drug response. In Western Switzerland, convergent technologies are being integrated into the diagnostic sector, with microfluidic chips, biosensors, genomics and advanced diagnostic imaging directed towards develop ing non-invasive technologies for increased patient comfort.
ABIONIC Revolutionizing the world of in vitro diagnostics
Founded in 2010 by Nicolas Durand and Iwan Märki, Abionic developped its nano-, bio- and medical- technology within the Swiss federal Institute of Technology in Lausanne (EPFL).
Already in 2012, Abionic obtained the ISO 13485 quality certification for research and development, production and marketing of products for the in-vitro diagnostics market. The company’s benchmark is winning no less than 20 prestigious startup awards and 4 times best med-tech startup. In 2012, Abionic finalized a Series A financing round and in 2014, a Series B financing for a total of CHF 8.2 million led by MedHoldings SA and including Polytech Ventures & Cie SCPC, Blue Ocean Ventures, Business Angels Switzerland (BAS) and Fongit Seed Invest. The ultra-fast abioSCOPE, a CE-marked reading system designed to detect allergies received the «Swiss Excellence Product» allergies, received the «Swiss Excellence Product» award in 2013 and the world’s fastest blood test diagnostic platform that detects killer SEPSIS, filled FDA registration in 2017, brings nanotechnology directly to healthcare professionals for everybody’s wellbeing.
A rich environment for development
Western Switzerland offers a robust array of business and academic institutions with leading technologies and research in the field of diagnostics, whether IVD, diagnostic imaging or molecular diagnostics. Academic laboratories and companies cross-fertilize successfully to create a dynamic, entrepreneurial environment to push the boundaries of knowledge.
The leading academic diagnostics research in western Switzerland
Geneva University UNIGE &
Geneva University Hospitals HUG &
Swiss Bioinformatics Institute SIB
Department of Genetic & Laboratory Medicine and Laboratory Medicine service
Diagnostic imaging, neurodiagnostics cytopathology, genetic diagnostics, molecular diagnostics New medical diagnostics based on biomarkers, human toxicology and bioinformatics
Geneva University UNIGE & Geneva University Hospitals HUG in collaboration with the Swiss Federal Institute of Technology Lausanne EPFL
Institute of Molecular Imaging
Translational molecular imaging or animal imaging, nanotechnology, radiation chemistry, and modeling and focus on neuro-imaging, chronic diseases, neurological degeneration,
University Hospital of Lausanne CHUV
Institute of Microbiology
Microbiology diagnosis of infectious diseases
Swiss Federal Institute of Technology Lausanne EPFL & Geneva University UNIGE
Medical Image Processing Lab
Interface between signal processing and medical imaging, signal and image processing and functional imaging.
Swiss Federal Institute of Technology EPFL
School of Engineering Institute of Microengineering Laboratory of Microsystems
BioMicrosystens - Microfluidic, lab-on-a-chip, BioMems for handling, analysis and culture of biological cells
Centre Suisse d’ Electronique
et de Microtechnique CSEM
Nanotechnology & Life Sciences
BioMicrosystems – integrated biosensing and monitoring biomechanics, micro-cell reactors, toxicology, biofunctional surface engineering
BioMicrosystems – ion-selective sensing, immunosensing, electrochemical sensing
Laboratory Instrumentation & Automation
BioMicrosystems – microfluidics, liquid handling, cell handling, sensor integration, robotics and automation
University of Applied Science – Western Switzerland HES-SO Valais
Institute Life Technologies
In vitro medical diagnostic (IVD) systems of molecular (nucleic acid, PCR) and immunochemistry (peptides, proteins) based platforms
University of Berne UNIBE
Institute for Veterinary Bacteriology
Diagnostic Laboratories of the Vetsuisse Faculty
In vitro diagnostic pathology including necropsies and biopsies of pet and food animals as well as exotic animals, wild life and fish
Department of Chemistry and Biochemistry
Genetic diagnostics using excimer- based molecular beacons and molecular diagnostics using molecular probes for the detection of homopurine sequences
University of Applied Science – Western Switzerland HEIG-VD
BioMicrosystems - biochips Diagnostic imaging: Image processing and visualization
Non exhaustive list of innovative diagnostics companies in the Bioalps cluster
The fact sheet provides a view of the key players in the sector at any given time; it is not comprehensive and is subject to regular updates.
This current edition was produced in Autumn 2019.